A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients
NCT03536143
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
BIOLOGICAL:
Topical beremagene geperpavec
BIOLOGICAL:
Placebo gel
Sponsor
Krystal Biotech, Inc.